Catalyst Category

SPA Agreement

Live feed of every SPA Agreement catalyst in Regulatory and Clinical.

CATALYSTS IN FEED

167

AVG MAX MOVE

+101.8%

POSITIVE MOVES

100%

LARGEST MOVE

+664.1%

Regulatory and ClinicalSPA AgreementSep 24, 2026 · 6:07am ET

ATYRaTYR PHARMA INC

aTyr Pharma Reaches FDA Alignment on Phase 3 Study Protocol for Efzofitimod

Company expects to initiate study-related activities in Q4 2026.

Regulatory and ClinicalSPA AgreementSep 24, 2026 · 6:07am ET

ATYRaTYR PHARMA INC+90.1%

aTyr Pharma Reaches FDA Alignment on Phase 3 Study Protocol for Efzofitimod

Regulatory and ClinicalSPA AgreementJun 9, 2026 · 7:06am ET

ATHEALTERITY THERAPEUTICS LTD

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

FDA agrees to Phase 3 design including UMSARS Part I as primary endpoint.

Regulatory and ClinicalSPA AgreementJun 9, 2026 · 7:06am ET

ATHEALTERITY THERAPEUTICS LTD+57.2%

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

Be first on the next Regulatory and Clinical catalyst.

Day Trader Sniper alerts you the instant a setup like this triggers.

Download Free →

Loading…

SPA Agreement

aTyr Pharma Reaches FDA Alignment on Phase 3 Study Protocol for Efzofitimod

aTyr Pharma Reaches FDA Alignment on Phase 3 Study Protocol for Efzofitimod

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

SPA Agreement

aTyr Pharma Reaches FDA Alignment on Phase 3 Study Protocol for Efzofitimod

aTyr Pharma Reaches FDA Alignment on Phase 3 Study Protocol for Efzofitimod

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

Alterity Therapeutics Aligns with FDA on Phase 3 ATH434 Program

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.